J
Jean Luc Harousseau
Researcher at University of Nantes
Publications - 82
Citations - 16270
Jean Luc Harousseau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 46, co-authored 82 publications receiving 14925 citations. Previous affiliations of Jean Luc Harousseau include University of Pennsylvania & Hotel Dieu Hospital.
Papers
More filters
Journal ArticleDOI
VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial.
Jean Luc Harousseau,Claire Mathiot,Michel Attal,Gerald Marit,Denis Caillot,Mohamad Mohty,Cyrille Hullin,Thierry Facon,Iain I.W. Webb,Philippe Moreau +9 more
TL;DR: This analysis not only confirms that the post-induction CR rate is increased by Vel/D compared to VAD but also shows that this benefit translates in higher CR+VGPR rates after ASCT.
Journal ArticleDOI
Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma
Heinz Ludwig,Luisa Viterbo,Richard Greil,Tamas Masszi,Ivan Spicka,Ofer Shpilberg,Roman Hájek,Anna Dmoszynska,Bruno Paiva,María Belén Vidriales,Graça Esteves,Anne-Marie Stoppa,Don Robinson,Deborah Ricci,Andrew Cakana,Christopher Enny,Huaibao Feng,Helgi van de Velde,Jean Luc Harousseau +18 more
TL;DR: Both VTD and VTDC are highly active induction regimens producing high combined CR/nCR and MRD-negative rates; however, VTDC was associated with increased toxicity and suggestion of transient decreases in Global Health score, without an increase in activity.
Journal ArticleDOI
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Pieter Sonneveld,Roman Hájek,Arnon Nagler,Andrew Spencer,Joan Bladé,Tadeusz Robak,Sen H. Zhuang,Jean Luc Harousseau,Robert Z. Orlowski +8 more
TL;DR: In the current analysis, the efficacy and safety profile of PLD plus bortezomib in IMiD‐exposed and IMid‐naive patients is determined.
Journal ArticleDOI
Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation
Norbert Claude Gorin,Myriam Labopin,Francesco Frassoni,Noel Milpied,Michel Attal,Didier Blaise,Giovanna Meloni,Anna Paola Iori,Mauricette Michallet,Roel Willemze,Eric Deconninck,Jean Luc Harousseau,Emmanuelle Polge,Vanderson Rocha +13 more
TL;DR: Patients with acute myelocytic leukemia carrying inversion 16 or t(8;21) have a better initial response to high-dose cytarabine than patients without these chromosomal abnormalities and both autologous and allogeneic transplantation resulted in similar outcomes.
Journal ArticleDOI
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
TL;DR: Current myeloma therapy is examined from a pharmacoeconomic perspective, the underlying reasons why cancer drugs are so expensive, the measures that are required to lower cost, and proposed potential ways in which costs can be reduced while still delivering high-quality care.